- Thomson Reuters StreetEvents via Yahoo FinanceNov 11 23:40 PM
We will present additional interim data from our ongoing Phase I/II clinical trial of cirmtuzumab in combination with ibrutinib in patients with CLL or MCL at the American Society of Hematology ...
- Thomson Reuters StreetEvents via Yahoo Finance1 day ago
- The National Law Review20 hours ago
- MSN News6 days ago